Surgical, Oncological, and Functional Outcomes of Transoral Robotic Supraglottic Laryngectomy.
Academic Medical Centers
/ statistics & numerical data
Adult
Aged
Blood Loss, Surgical
/ statistics & numerical data
Disease-Free Survival
Female
Follow-Up Studies
Humans
Laryngeal Neoplasms
/ diagnosis
Laryngectomy
/ adverse effects
Length of Stay
/ statistics & numerical data
Male
Middle Aged
Natural Orifice Endoscopic Surgery
/ adverse effects
Neoplasm Staging
Operative Time
Postoperative Hemorrhage
/ epidemiology
Radiotherapy, Adjuvant
/ adverse effects
Retrospective Studies
Robotic Surgical Procedures
/ adverse effects
Laryngectomy
cancer
laryngeal
larynx
outcomes
partial
robot
robotic
supraglottic
transoral
Journal
The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
09
06
2020
received:
18
02
2020
accepted:
17
06
2020
pubmed:
20
8
2020
medline:
8
5
2021
entrez:
20
8
2020
Statut:
ppublish
Résumé
To investigate the surgical, oncological, and functional outcomes of transoral robotic surgery (TORS) for the treatment of supraglottic squamous cell carcinoma. Retrospective chart review. The charts of patients treated by TORS supraglottic laryngectomy (SGL) in an academic medical center were reviewed. The following outcomes were studied according to the tumor location: average robotic setup and operative times, mean estimated blood loss, postoperative complications, need of tracheotomy, refeeding characteristics, mean hospital stay, need of neck dissection and adjuvant therapy, 5-year local and regional controls, overall survival (OS), and disease-free survival (DFS). Seventy-five patients underwent TORS SGL. Tumors were classified as cT1 (32%), cT2 (52%), and cT3 (16%). Average robotic setup and operative times and the mean estimated blood loss were 15 minutes, 55 minutes, and 20 mL, respectively. The mean follow-up period ranged from 2 to 5 years. The 5-year OS and DFS were 80.2% and 94.3%, respectively. Overall, 34.6% of patients received adjuvant radiotherapy. The majority of patients (92%) restarted an oral diet within 24 to 48 hours postsurgery. Transient tracheotomy was performed in 8% of patients. Postoperative hemorrhages occurred in 12 patients (16.0%), lengthening the hospital stay (mean = 6.8 days). There were no outcome differences regarding the tumor location. TORS is an effective and safe therapeutic approach for early- and intermediate-stages cancers. Oncological outcomes may be quite similar to other surgical approaches, including transoral laser and open surgeries. Future randomized controlled studies are needed for comparing TORS SGL with other surgical procedures. 4 Laryngoscope, 131:1060-1065, 2021.
Types de publication
Journal Article
Video-Audio Media
Langues
eng
Sous-ensembles de citation
IM
Pagination
1060-1065Informations de copyright
© 2020 The American Laryngological, Rhinological and Otological Society, Inc.
Références
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386.
Mendelsohn AH, Remacle M. Transoral robotic surgery for laryngeal cancer. Curr Opin Otolaryngol Head Neck Surg 2015;23:148-152.
Mendelsohn AH, Remacle M, Van Der Vorst S, Bachy V, Lawson G. Outcomes following transoral robotic surgery: supraglottic laryngectomy: TORS supraglottic laryngectomy. Laryngoscope 2013;123:208-214.
Weinstein GS, O'Malley BW Jr, Snyder W, Hockstein NG. Transoral robotic surgery: supraglottic partial laryngectomy. Ann Otol Rhinol Laryngol 2007;116:19-23.
Solares CA, Strome M. Transoral robot-assisted CO2 laser supraglottic laryngectomy: experimental and clinical data. Laryngoscope 2007;117:817-820.
Boudreaux BA, Rosenthal EL, Magnuson JS, et al. Robot-assisted surgery for upper aerodigestive tract neoplasms. Arch Otolaryngol Head Neck Surg 2009;135:397-401.
Doazan M, Hans S, Morinière S, et al. Oncologic outcomes with transoral robotic surgery for supraglottic squamous cell carcinoma: results of the French robotic surgery group of GETTEC. Head Neck 2018;40:2050-2059.
Ansarin M, Zorzi S, Massaro MA, et al. Transoral robotic surgery vs transoral laser microsurgery for resection of supraglottic cancer: a pilot surgery. Int J Med Robot 2014;10:107-112.
Lallemant B, Chambon G, Garrel R, et al. Transoral robotic surgery for the treatment of T1-T2 carcinoma of the larynx: preliminary study. Laryngoscope 2013;123:2485-2490.
Nakayama M, Holsinger FC, Orosco RK. Hybrid supracricoid partial laryngectomy with cricohyoidoepiglottopexy via transoral robotic surgery. Laryngoscope 2019;129:2065-2070.
de Almeida JR, Li R, Magnuson JS, Smith RV, et al. Oncologic outcomes after transoral robotic surgery: a multi-institutional study. JAMA Otolaryngol Head Neck Surg 2015;141:1043-1051.
Remacle M, Hantzakos A, Eckel H, et al. Endoscopic supraglottic laryngectomy: a proposal for a classification by the Working Committee on Nomenclature, European Laryngological Society. Eur Arch Otorhinolaryngol 2009;266:993-998.
Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours. 7th ed. Oxford, United Kingdom: Wiley-Blackwell; 2009.
Ozer E, Alvarez B, Kakarala K, Durmus K, Teknos TN, Carrau RL. Clinical outcomes of transoral robotic supraglottic laryngectomy. Head Neck 2013;35:1158-1161.
Stubbs VC, Rajasekaran K, Gigliotti AR, et al. Management of the airway for transoral robotic supraglottic partial laryngectomy. Front Oncol 2018;8:312.
Mandal R, Duvvuri U, Ferris RL, Kaffenberger TM, Choby GW, Kim S. Analysis of post-transoral robotic-assisted surgery hemorrhage: frequency, outcomes, and prevention. Head Neck 2016;38:E776-E782.
Razafindranaly V, Lallemant B, Aubry K, et al. Clinical outcomes with transoral robotic surgery for supraglottic squamous cell carcinoma: experience of a French evaluation cooperative subgroup of GETTEC. Head Neck 2016;38:E1097-E1101.
Peretti G, Piazza C, Ansarin M, et al. Transoral CO2 laser microsurgery for tis-T3 supraglottic squamous cell carcinomas. Eur Arch Otorhinolaryngol 2010;267:1735-1742.
Ambrosch P, Gonzalez-Donate M, Fazel A, Schmalz C, Hedderich J. Transoral laser microsurgery for supraglottic cancer. Front Oncol 2018;8:158.